Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management

Hepatology

Volumn 64, Issue 4, 2016, Pages 1121-1135

  Nicolle, Delphine ^a   Fabre, Monique ^b   Simon Coma, Marina ^c,d   Gorse, Aurore ^a   Kappler, Roland ^e   Nonell, Lara ^f   Mallo, Mar ^g   Haidar, Hazar ^h   Déas, Olivier ^a   Mussini, Charlotte ^h   Guettier, Catherine ^h   Redon, Marie José ^h   Brugières, Laurence ⁱ   Ghigna, Maria Rosa ^j   Fadel, Elie ^j   Galmiche Rolland, Louise ^b   Chardot, Christophe ^b   Judde, Jean Gabriel ^a   Armengol, Carolina ^c,d   Branchereau, Sophie ^h   Cairo, Stefano ^a,k   more..

^a XenTech   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Germans Trias i Pujol Health Research Institute   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f HOSPITAL DEL MAR   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h BICÊTRE HOSPITAL   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^k UNIVERSITY OF FERRARA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; IRINOTECAN; TEMOZOLOMIDE;

ADVERSE OUTCOME; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CHILDHOOD CANCER; CHROMOSOME 17; CHROMOSOME 20; CHROMOSOME 4; CHROMOSOME 8; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HEPATOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOUSE; MUTATION RATE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; RHABDOID TUMOR; ANIMAL; CANCER TRANSPLANTATION; CHILD; EXPERIMENTAL NEOPLASM; LIVER NEOPLASMS; MALE; PROGNOSIS; TUMOR RECURRENCE; XENOGRAFT;

ANIMALS; CHILD; FEMALE; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MALE; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROGNOSIS;

EID: 84977501385     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28621     Document Type: Article

References (46)

1. Vassal G, Fitzgerald E, Schrappe M, Arnold F, Kowalczyk J, Walker D, et al. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda. Pediatr Blood Cancer 2014;61:1551-1557.
2. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002;20:2789-2797.
3. Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D, et al. Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002;20:2798-2804.
4. Czauderna P. Adult type vs. childhood hepatocellular carcinoma—are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 2002;39:519-523.
5. Prokurat A, Kluge P, Kościesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002;39:510-518.
6. Zimmermann A. The emerging family of hepatoblastoma tumors: from ontogenesis to oncogenesis. Eur J Cancer 2005;41:1503-1514.
7. Perilongo G, Shafford EA. Liver tumours. Eur J Cancer 1999;35:953-958.
8. Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Wharton KA, et al. Elevated expression of wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005;11:4295-4304.
9. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21:4863-4871.
10. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000;19:498-504.
11. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr 2005;147:263-266.
12. Hamada Y, Takada K, Fukunaga S, Hioki K. Hepatoblastoma associated with Beckwith-Wiedemann syndrome and hemihypertrophy. Pediatr Surg Int 2003;19:112-114.
13. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361:1662-1670.
14. Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall'Igna P, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer 2012;48:1543-1549.
15. Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010;28:2584-2590.
16. Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al. International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 2013;14:834-842.
17. Jia D, Dong R, Jing Y, Xu D, Wang Q, Chen L, et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology 2014;60:1686-1696.
18. Eichenmüller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Häberle B, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol 2014;61:1312-1320.
19. Vilarinho S, Choi M, Jain D, Malhotra A, Kulkarni S, Pashankar D, et al. Individual exome analysis in diagnosis and management of pediatric liver failure of indeterminate aetiology. J Hepatol 2014;61:1056-1063.
20. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343:1010-1014.
21. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012;122:2983-2988.
22. Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, et al. β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res 2014;74:4515-4525.
23. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, et al. Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology 2015;62:851-862.
24. Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta 2015;1855:223-234.
25. Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 2015;21:1318-1325.
26. Hata Y, Uchino J, Sato K, Sasaki F, Une Y, Naito H, et al. Establishment of an experimental model of human hepatoblastoma. Cancer 1982;50:97-101.
27. Desdouets C, Fabre M, Gauthier F, Bréchot C, Sobczak-Thépot J. Proliferation and differentiation of a human hepatoblastoma transplanted in the Nude mouse. J Hepatol 1995;23:569-577.
28. Fuchs J, Schmidt D, Pietsch T, Miller K, von Schweinitz D. Successful transplantation of human hepatoblastoma into immunodeficient mice. J Pediatr Surg 1996;31:1241-1246.
29. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14:471-484.
30. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. ISBN 3-900051-07-0.
31. Yan YHC. OmicCircos: high-quality circular visualization of Omic data. R package version 1.5.1; 2015.
32. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 2012;18:3846-3855.
33. National Cancer Institute PPTP program. Testing and analysis methods, http://ctep.cancer.gov/content/docs/PPPTP_TESTING_AND_ANALYSIS_METHODS.pdf. Accessed on: June 1, 2016.
34. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol 2015;33:2472-2480.
35. Hu J, Wills M, Baker BA, Perlman EJ. Comparative genomic hybridization analysis of hepatoblastomas. Genes Chromosomes Cancer 2000;27:196-201.
36. Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000;157:571-578.
37. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10:34-42.
38. Grotegut S, Kappler R, Tarimoradi S, Lehembre F, Christofori G, Von Schweinitz D. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int J Oncol 2010;36:1261-1267.
39. Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer 2009;52:346-350.
40. Poon R, Hong H, Wei X, Pan J, Alman BA. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One 2012;7:e37940.
41. Zsíros J, Brugières L, Brock P, Roebuck D, Maibach R, Child M, et al. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma: a phase II trial of the childhood liver tumour strategy group (SIOPEL). Eur J Cancer 2012;48:3456-3464.
42. Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271-5276.
43. Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:1029-1034.
44. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
45. Mathijssen RHJ, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-2194.
46. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015;15:311-316.